EMBRACEPhysician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer
Section snippets
Patients
The EMBRACE study opened in July 2008 and finalised accrual in December 2015 with 1416 patients from 24 centres. Patients eligible for inclusion in the EMBRACE study were previously untreated, biopsy proven cervical cancer, FIGO stage IB-IVA (and stage IVB with metastatic nodes below L1 only) treated with curative definitive radio (chemo)therapy and IGABT.
For this urinary morbidity analysis, patients were excluded when: not meeting the selection criteria or not receiving treatment as planned (n
Results
In the 1176 patients analysed in this study, the median FU was 27 (1–83) months. The patient, disease and treatment characteristics are reported in Table 1.
Baseline urinary symptoms
Prevalence of individual urinary symptoms at BL included mainly urinary frequency or incontinence. For other endpoints, few patients had symptoms at BL (Appendix 1).
Incidence of urinary symptoms during follow up (FU)
Crude maximum incidence of individual urinary symptoms showed mainly mild (grade 1) to moderate (grade 2) symptoms (Table 2). Urinary frequency, incontinence and cystitis were the endpoints most commonly reported (Table 2). The actuarial probability that a patient had any bladder morbidity (≥grade 1) within 3/5-years was 69.8%
Baseline incidence of PRO
Prevalence of PRO before treatment included mainly “urine frequency”, while “leaking of urine”, “pain/burning feeling when passing urine” or “difficulty emptying the bladder” was reported by a smaller proportion of the patients (Appendix 2).
Patient reported outcome (PRO) versus physician assessed morbidity
Associations between physician assessed and PRO urinary frequency as well as PRO and incontinence were found. In consultations where the physician scored the patient as having CTCAE grade 2 frequency or incontinence, 70.9% and 62.3% reported themselves ≥“quite a bit” or “very much” bother, respectively. For CTCAE grade 1, this was 35.0% and 19.3%, and for CTCAE score 0, this was 8.9% and 2.0%, respectively (Fig. 4).
Discussion
This EMBRACE report includes 1176 patients with LACC treated with definitive (chemo)radiotherapy including IGABT. The EMBRACE study provides systematically recorded prospective longitudinal information on physician assessed morbidity and PRO; and this report adds to previously published EMBRACE reports on vaginal and rectal toxicity [19], [20], [21].
The risk of severe to life-threatening grade 3–4 urinary morbidity was 5.3%/6.3% at 3/5-years and included all individual bladder endpoints and
Conclusion
This large prospective study with longitudinal data collection provides a detailed and comprehensive overview of urinary morbidity. The study will serve as benchmark in future IGABT for LACC. It demonstrates that severe bladder morbidity after IGABT is limited and compares favourably to 2D brachytherapy. Mild to moderate morbidity is still relatively pronounced especially with a high level of urinary frequency and progressively increasing incontinence according to both physician and patient
Conflict of interest
None.
Acknowledgements
Inclusion of patients in the EMBRACE 1 study was done by centres in the EMBRACE collaborative group (Appendix 4).
EMBRACE was supported by Nucletron, an Elekta company and Varian Medical System through grants and study sponsoring through Vienna Medical University and research grants from The Danish Cancer Society (grant number R125-A7753-15-S37).
References (32)
- et al.
Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients
Int J Radiat Oncol Biol Phys
(2009) - et al.
Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study
Radiother Oncol
(2012) - et al.
Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience
Radiother Oncol
(2013) - et al.
Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer
Radiother Oncol
(2011) - et al.
Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy
Gynecol Oncol
(2014) - et al.
Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study
Radiother Oncol
(2016) - et al.
Clinical impact of computed tomography-based image-guided brachytherapy for cervix cancer using the tandem-ring applicator – the Addenbrooke's experience
Clin Oncol (R Coll Radiol)
(2009) - et al.
MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer
Int J Radiat Oncol Biol Phys
(2008) - et al.
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
Radiother Oncol
(2006) - et al.
From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer
Radiother Oncol
(2010)